104 related articles for article (PubMed ID: 24299208)
21. Activation of the PI3K/AKT signalling pathway in non-melanoma skin cancer is not mediated by oncogenic PIK3CA and AKT1 hotspot mutations.
Hafner C; Landthaler M; Vogt T
Exp Dermatol; 2010 Aug; 19(8):e222-7. PubMed ID: 20557351
[TBL] [Abstract][Full Text] [Related]
22. PIK3CA mutations and loss of ARID1A protein expression are early events in the development of cystic ovarian clear cell adenocarcinoma.
Yamamoto S; Tsuda H; Takano M; Tamai S; Matsubara O
Virchows Arch; 2012 Jan; 460(1):77-87. PubMed ID: 22120431
[TBL] [Abstract][Full Text] [Related]
23. The association of PI3 kinase signaling and chemoresistance in advanced ovarian cancer.
Carden CP; Stewart A; Thavasu P; Kipps E; Pope L; Crespo M; Miranda S; Attard G; Garrett MD; Clarke PA; Workman P; de Bono JS; Gore M; Kaye SB; Banerji U
Mol Cancer Ther; 2012 Jul; 11(7):1609-17. PubMed ID: 22556379
[TBL] [Abstract][Full Text] [Related]
24. Mutation of the PIK3CA gene in ovarian and breast cancer.
Campbell IG; Russell SE; Choong DY; Montgomery KG; Ciavarella ML; Hooi CS; Cristiano BE; Pearson RB; Phillips WA
Cancer Res; 2004 Nov; 64(21):7678-81. PubMed ID: 15520168
[TBL] [Abstract][Full Text] [Related]
25. Mutation and genomic amplification of the PIK3CA proto-oncogene in pituitary adenomas.
Murat CB; Braga PB; Fortes MA; Bronstein MD; Corrêa-Giannella ML; Giorgi RR
Braz J Med Biol Res; 2012 Sep; 45(9):851-5. PubMed ID: 22782554
[TBL] [Abstract][Full Text] [Related]
26. Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.
Juanpere N; Agell L; Lorenzo M; de Muga S; López-Vilaró L; Murillo R; Mojal S; Serrano S; Lorente JA; Lloreta J; Hernández S
Hum Pathol; 2012 Oct; 43(10):1573-82. PubMed ID: 22417847
[TBL] [Abstract][Full Text] [Related]
27. Mucinous breast carcinomas lack PIK3CA and AKT1 mutations.
Kehr EL; Jorns JM; Ang D; Warrick A; Neff T; Degnin M; Lewis R; Beadling C; Corless CL; Troxell ML
Hum Pathol; 2012 Dec; 43(12):2207-12. PubMed ID: 22705004
[TBL] [Abstract][Full Text] [Related]
28. Whole-genome sequencing revealed novel prognostic biomarkers and promising targets for therapy of ovarian clear cell carcinoma.
Itamochi H; Oishi T; Oumi N; Takeuchi S; Yoshihara K; Mikami M; Yaegashi N; Terao Y; Takehara K; Ushijima K; Watari H; Aoki D; Kimura T; Nakamura T; Yokoyama Y; Kigawa J; Sugiyama T
Br J Cancer; 2017 Aug; 117(5):717-724. PubMed ID: 28728166
[TBL] [Abstract][Full Text] [Related]
29. Identification of somatic genetic alterations in ovarian clear cell carcinoma with next generation sequencing.
Shibuya Y; Tokunaga H; Saito S; Shimokawa K; Katsuoka F; Bin L; Kojima K; Nagasaki M; Yamamoto M; Yaegashi N; Yasuda J
Genes Chromosomes Cancer; 2018 Feb; 57(2):51-60. PubMed ID: 29044863
[TBL] [Abstract][Full Text] [Related]
30. Characterization of Mutational Status, Spheroid Formation, and Drug Response of a New Genomically-Stable Human Ovarian Clear Cell Carcinoma Cell Line, 105C.
Kolendowski B; Valdes YR; Hirte H; Itamochi H; Lee W; Carey M; Shepherd TG; DiMattia GE
Cells; 2020 Nov; 9(11):. PubMed ID: 33153119
[TBL] [Abstract][Full Text] [Related]
31. PIK3CA mutations in head and neck squamous cell carcinoma.
Qiu W; Schönleben F; Li X; Ho DJ; Close LG; Manolidis S; Bennett BP; Su GH
Clin Cancer Res; 2006 Mar; 12(5):1441-6. PubMed ID: 16533766
[TBL] [Abstract][Full Text] [Related]
32. Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma.
Caumanns JJ; Berns K; Wisman GBA; Fehrmann RSN; Tomar T; Klip H; Meersma GJ; Hijmans EM; Gennissen AMC; Duiker EW; Weening D; Itamochi H; Kluin RJC; Reyners AKL; Birrer MJ; Salvesen HB; Vergote I; van Nieuwenhuysen E; Brenton J; Braicu EI; Kupryjanczyk J; Spiewankiewicz B; Mittempergher L; Bernards R; van der Zee AGJ; de Jong S
Clin Cancer Res; 2018 Aug; 24(16):3928-3940. PubMed ID: 29685880
[No Abstract] [Full Text] [Related]
33. Targeted sequencing of a specific gene panel detects a high frequency of ARID1A and PIK3CA mutations in ovarian clear cell carcinoma.
Su YF; Tsai EM; Chen CC; Wu CC; Er TK
Clin Chim Acta; 2019 Jul; 494():1-7. PubMed ID: 30851247
[TBL] [Abstract][Full Text] [Related]
34. PIK3CA in ovarian clear cell carcinoma.
Zannoni GF; Improta G; Fraggetta F
Hum Pathol; 2014 Dec; 45(12):2514. PubMed ID: 25245602
[No Abstract] [Full Text] [Related]
35. PIK3CA mutations in ovarian cancer.
Campbell IG; Russell SE; Phillips WA
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):7042; author reply 7042-3. PubMed ID: 16203798
[No Abstract] [Full Text] [Related]
36. Occurrence of low frequency PIK3CA and AKT2 mutations in gastric cancer.
Zhang QY; Cheng WX; Li WM; Au W; Lu YY
Mutat Res; 2014 Nov; 769():108-12. PubMed ID: 25771729
[TBL] [Abstract][Full Text] [Related]
37. Somatic copy number alterations have prognostic impact in patients with ovarian clear cell carcinoma.
Morikawa A; Hayashi T; Kobayashi M; Kato Y; Shirahige K; Itoh T; Urashima M; Okamoto A; Akiyama T
Oncol Rep; 2018 Jul; 40(1):309-318. PubMed ID: 29749539
[TBL] [Abstract][Full Text] [Related]
38. Coexistent ARID1A-PIK3CA mutations promote ovarian clear-cell tumorigenesis through pro-tumorigenic inflammatory cytokine signalling.
Chandler RL; Damrauer JS; Raab JR; Schisler JC; Wilkerson MD; Didion JP; Starmer J; Serber D; Yee D; Xiong J; Darr DB; Pardo-Manuel de Villena F; Kim WY; Magnuson T
Nat Commun; 2015 Jan; 6():6118. PubMed ID: 25625625
[TBL] [Abstract][Full Text] [Related]
39. PIK3CA-AKT pathway mutations in micropapillary breast carcinoma.
Flatley E; Ang D; Warrick A; Beadling C; Corless CL; Troxell ML
Hum Pathol; 2013 Jul; 44(7):1320-7. PubMed ID: 23352210
[TBL] [Abstract][Full Text] [Related]
40. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma.
Jones S; Wang TL; Shih IeM; Mao TL; Nakayama K; Roden R; Glas R; Slamon D; Diaz LA; Vogelstein B; Kinzler KW; Velculescu VE; Papadopoulos N
Science; 2010 Oct; 330(6001):228-31. PubMed ID: 20826764
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
